Objective: Oncogenic human papillomavirus (HPV) has been established as a causative agent for 25% of head and neck squamous cell cancer (HNSCC), including laryngeal squamous cell cancer (LSCC). HPV-positive oropharyngeal patients have improved prognosis. We determined outcomes in LSCC in the context of HPV infection.
Objective: Oculopharyngeal muscular dystrophy (OPMD) is a rare, autosomal dominant, progressive degenerative muscle disorder featuring dysphagia with limited therapeutic options. Cricopharyngeal myotomy improves symptoms, yet dysphagia frequently recurs, failing to prevent aspiration and enteral feeding. The objective is to evaluate safety and efficacy of repeated endoscopic dilatation for OPMD over a 15-year period.
Method: All patients at our unit with genetically confirmed OPMD were included. Cricopharyngeal dilatation was performed with a wire-guided 18 mm Savary-Gilliard bougie. Repeat dilatation was offered when symptoms recurred. Symptom severity prior to initial dilatation and at follow-up was evaluated using the Sydney Swallow Questionnaire (SSQ).
Results: Nine patients (7 female, 2 male) were included. Median total treatment period was 13 years (range, 3-15 years), median number of dilatations per patient was 7.2 (1-16), and median interval between treatments was 15 months (range, 4.5-45 months). All patients recorded sustained symptom improvement. Mean SSQ score was 1108 out of 1700 (SD ± 272.9) prior to first dilatation and 298 out of 1700 (SD ± 189.1) at last follow-up, representing a 73% decrease (95% CI 52-94) in degree of dysphagia symptoms (Paired t test, P = .0001). All mean scores for individual questions also showed significant improvement (P < .05). No adverse events were reported with all patients maintaining oral feeding at last follow-up.
Conclusion: Repeated cricopharyngeal dilatation is a safe, effective, well-tolerated, and long-lasting treatment for dysphagia in OPMD.
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Mometasone Furoate in Patients with Eosinophilic Esophagitis
Henrik Bergquist, MD, PhD (presenter); Helen Larsson; Leif Johansson; MD, PhD; Mogens Bove; MD, PhD Objective: The treatment of patients with eosinophilic esophagitis remains challenging. The effects of the current first-choice treatment, ie, topical corticosteroids, are still inadequately surveyed. Our aim was to assess dysphagia and health-related quality of life using validated scales and questionnaires before and after treatment with mometasone furoate.
Method: Newly diagnosed, untreated adult patients with eosinophilic esophagitis were included and given 200 µg of orally administered topical mometasone furoate 4 times daily. Questionnaires, incorporating the Watson Dysphagia Scale, the EORTC QLQ-OES18, and the SF-36, were completed before and after 2 months of treatment.
Results: Thirty-one consecutive patients (22 males, mean age 45, range 18-89) completed the trial. At inclusion, the mean scores of the Watson Dysphagia Scale, the EORTC QLQ-OES18 dysphagia scale, eating scale and choking item, and the SF-36 global health dimension and social functioning dimension were 21.3, 20.4, 35.0, 38.6, 71 .1, and 82.3, respectively. Posttreatment, these scores improved to 8.9 (P < .0001), 4.6 (P < .00001), 17.8 (P < .001), 16.0 (P < .01), 76.1 (P < .05) and 91.9 (P = .0001), respectively. Except for one case of oral candidiasis, no significant side effects were reported.
Conclusion: Treatment with 2 months of orally administered mometasone furoate seems to have a beneficial effect on dysphagia and health-related quality of life in the majority of
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adult patients with eosinophilic esophagitis. However, a randomized placebo-controlled trial is warranted in order to verify this.
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Novel MicroRNA miR-923 is Dysregulated in Primary lSCC Kang Mei Chen, MD (presenter); Josena K. Stephen; Shaleta Harvard; Glendon M. Gardner, MD; Vanessa Schweitzer, MD; Veena Shah, MD; Maria J. Worsham, PhD
Objective: MicroRNAs (miRNAs) are endogenous, small, noncoding RNAs of 17 to 25 nucleotides that regulate approximately 30% of human genes. They are differentially expressed in various types of cancers compared with noncancerous tissues, suggesting that they may have crucial roles in tumorigenesis. The objective of this study was to discover LSCC-specific miRNAs.
Method: Global miRNA profiling (800 human miRNAs plus 10 endogenous control miRNAs) was performed on 8 formalin-fixed archival LSCC samples and 5 normal laryngeal squamous epithelium (HTG, Tucson, AZ, USA). Quantitative real-time PCR (qRT-PCR) approach was employed to verify expression status of selected miRNAs that were significantly different from normal controls.
Results: Thirty-one of the 800 human miRNAs were significantly differentially expressed (P < .05) between LSCC vs normal tissues. Selected miRNAs (miR-31, miR-193b, miR-663b, miR-923, and miR-1826), by qRT-PCR, verified expression of consistently upregulated miR-31 and miR-193b as well as differentially expressed miR-663b, miR-923, and miR-1826. Dysregulation of miR-923 was newly observed and showed upregulation in 3 out of 8 and downregulation in 5 out of 8 LSCC.
Conclusion:
We have identified a group of 31 aberrantly expressed miRNAs in LSCC. miR-923 has not been previously reported in HNSCC, including LSCC. Further detailed examinations of this miRNA will provide opportunities to dissect the complex molecular abnormalities driving LSCC.
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Proteomic Analysis of Decellularized Tissue Engineered laryngeal-Tracheal Scaffolds
Colin Butler (presenter); Justin Hsuan; Nick Beaumont; Sam Janes; Tahera Ansari; Martin Birchall, FRCS Objective: The clinical success of a fully tissue-engineered tracheal transplant has indicated that there may be more to using decellularized tissue as a scaffold construct. It has been hypothesized that remnant polypeptides reside in these matrices. We sought to determine the proteome profile of a decellularized laryngeal-tracheal scaffold construct.
Method: A laryngeal-tracheal construct was fabricated using standard decellularization protocols and underwent immunohistochemistry, electron microscopy, biomechanical analysis, and qPCR for total DNA content. Samples from anatomical subsites were prepared for proteomic analysis. Tandem massspectrometry (LC-MS/MS) was used to identify peptide sequences and validated using multicolor immunohistochemistry and western blotting.
Results: Decellularization of laryngea-tracheal scaffold airway construct effectively removed cells, MHC components, and DNA while maintaining similar biomechanical properties to native (nondecellularized) tissue. We identified variable expression of polypeptides in the anatomical subsites of the airway scaffold construct. A minimum core set of polypeptides was identified with a subset of proteins with putative roles beyond structural integrity. Of particular interest were small molecular weight polypeptides known to have significant roles in epithelialization and angiogenesis.
Objective: Using a functional model of airway granulation tissue in subglottic stenosis, we investigated changes in inflammatory markers within granulation tissue in response to intraperitoneal dexamethasone injections. Changes in inflammatory markers will allow us to identify potential targets for immunological therapy.
Method: Laryngotracheal complexes (LTCs) of donor mice underwent airway injury. Donor LTCs were transplanted into subcutaneous tissue of recipient mice in 2 groups: steroidtreated and untreated. The steroid-treated arm received intraperitoneal dexamethasone for 3 weeks. LTCs were then harvested. Granulation formation was measured; mRNA expression of TGF-beta and IL-1b was quantified.
Results: At 3 weeks' posttransplantation, there were statistically significant differences in observable granulation formation as well as mRNA expression of TGF-beta 1 and IL-1b in all groups within the steroid treated arm as compared to the untreated arm.
Conclusion: Systemic steroids have been used to prevent formation of granulation tissue. However, the study of immunologic markers and the corresponding changes with steroid
